N-Acetylcysteine Impact on Liver Enzymes in NAFLD Patients

Non-alcoholic fatty liver disease (NAFLD) is a common condition that affects many people worldwide. It's characterized by fat build-up in the liver, which can lead to liver dysfunction. Currently, there's no approved treatment for NAFLD, and those with increased liver enzymes are at a higher risk of developing serious complications like cirrhosis and end-stage liver disease. This study aims to explore the potential benefits of a drug called N-acetyl cysteine (NAC) in improving liver function in NAFLD patients with raised liver enzymes (ALT and AST). The study focuses on adults with NAFLD, as confirmed by an ultrasound, and elevated liver enzymes. Participants in this study will be divided into two groups. The first group will follow a diet plan and engage in daily brisk walking for 20 minutes. The second group will receive NAC (200mg twice daily) in addition to following the same diet plan and exercise routine. The drug will be provided to the participants at no cost. Over 12 weeks, researchers will monitor liver function tests and any potential side effects of NAC. The primary goal is to evaluate if NAC can lead to a positive change in liver enzymes (ALT and AST) compared to diet and exercise alone.